Description

This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-147 in subjects with apolipoprotein L1 (APOL1)-mediated focal segmental glomerulosclerosis (FSGS).

Is there compensation for this trial? Yes

Am I Eligible or this trial?

Below is the detailed inclusion and exclusion detail for the the trial. Some of these you may know and other we may need to test in order to determine if you are a good fit for the trial. If you are not sure, please fill out the form to the left and one of our researchers will call you to assist in determining this and answering any additional questions.

Criteria

Inclusion Criteria:

• APOL1 genotype of G1/G1, G2/G2, or G1/G2

• FSGS diagnosed by kidney biopsy

Exclusion Criteria:

• Evidence of non-APOL1-mediated FSGS

• Subjects with known sickle cell disease

• Solid organ or Bone marrow transplant

Other protocol defined Inclusion/Exclusion criteria may apply.